Elekta AB (publ) (EKTAF)
USD 5.0
(0.0%)
USD 5.0
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 | 3.28 Billion SEK | 27.86% |
| 2023 | 2.57 Billion SEK | 16.15% |
| 2022 | 2.68 Billion SEK | -16.85% |
| 2021 | 3.06 Billion SEK | -3.67% |
| 2020 | 2.94 Billion SEK | 19.11% |
| 2019 | 2.67 Billion SEK | 8.91% |
| 2018 | 2.47 Billion SEK | 25.77% |
| 2017 | 1.97 Billion SEK | 8.3% |
| 2016 | 1.82 Billion SEK | 25.69% |
| 2015 | 1.44 Billion SEK | -36.46% |
| 2014 | 2.11 Billion SEK | -4.36% |
| 2013 | 2.33 Billion SEK | 8.76% |
| 2012 | 2.2 Billion SEK | 24.28% |
| 2011 | 1.76 Billion SEK | 19.85% |
| 2010 | 1.47 Billion SEK | 35.08% |
| 2009 | 1.08 Billion SEK | 24.32% |
| 2008 | 876 Million SEK | 46.24% |
| 2007 | 599 Million SEK | -11.13% |
| 2006 | 674 Million SEK | 42.19% |
| 2005 | 474 Million SEK | 29.16% |
| 2004 | 367 Million SEK | -1.61% |
| 2003 | 373 Million SEK | 47.43% |
| 2002 | 253 Million SEK | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q4 | 858 Million SEK | 3.39% |
| 2024 Q1 | 617 Million SEK | -33.41% |
| 2024 FY | - SEK | 16.91% |
| 2024 Q2 | 774 Million SEK | 24.75% |
| 2024 Q3 | 794 Million SEK | 4.08% |
| 2023 Q2 | 510 Million SEK | 49.12% |
| 2023 Q3 | 705 Million SEK | 38.24% |
| 2023 Q4 | 1.04 Billion SEK | 48.79% |
| 2023 FY | - SEK | 16.15% |
| 2023 Q1 | 342 Million SEK | -50.79% |
| 2022 Q3 | 477 Million SEK | -26.28% |
| 2022 Q4 | 695 Million SEK | 45.7% |
| 2022 FY | - SEK | -16.85% |
| 2022 Q1 | 262 Million SEK | -65.93% |
| 2022 Q2 | 647 Million SEK | 146.95% |
| 2021 FY | - SEK | -3.67% |
| 2021 Q4 | 769 Million SEK | 2.81% |
| 2021 Q1 | 706 Million SEK | -26.38% |
| 2021 Q2 | 803 Million SEK | 13.74% |
| 2021 Q3 | 748 Million SEK | -6.85% |
| 2020 Q2 | 751 Million SEK | 24.34% |
| 2020 Q3 | 784 Million SEK | 4.39% |
| 2020 Q4 | 959 Million SEK | 22.32% |
| 2020 FY | - SEK | 19.11% |
| 2020 Q1 | 604 Million SEK | -40.67% |
| 2019 Q4 | 1.01 Billion SEK | 82.76% |
| 2019 Q3 | 557 Million SEK | -15.35% |
| 2019 Q1 | 447 Million SEK | -52.29% |
| 2019 Q2 | 658 Million SEK | 47.2% |
| 2019 FY | - SEK | 8.91% |
| 2018 Q2 | 622 Million SEK | 34.05% |
| 2018 Q4 | 937 Million SEK | 56.95% |
| 2018 FY | - SEK | 25.77% |
| 2018 Q1 | 464 Million SEK | -39.19% |
| 2018 Q3 | 597 Million SEK | -4.02% |
| 2017 Q3 | 507 Million SEK | 22.46% |
| 2017 FY | - SEK | 8.3% |
| 2017 Q1 | 210 Million SEK | -72.22% |
| 2017 Q4 | 763 Million SEK | 50.49% |
| 2017 Q2 | 414 Million SEK | 97.14% |
| 2016 FY | - SEK | 25.69% |
| 2016 Q4 | 756 Million SEK | 136.99% |
| 2016 Q1 | 90 Million SEK | -85.32% |
| 2016 Q3 | 319 Million SEK | -35.69% |
| 2016 Q2 | 496 Million SEK | 451.11% |
| 2015 FY | - SEK | -36.46% |
| 2015 Q3 | 388 Million SEK | -12.42% |
| 2015 Q4 | 613 Million SEK | 57.99% |
| 2015 Q1 | 4 Million SEK | -99.69% |
| 2015 Q2 | 443 Million SEK | 10975.0% |
| 2014 Q1 | 175 Million SEK | -85.37% |
| 2014 FY | - SEK | -4.36% |
| 2014 Q4 | 1.29 Billion SEK | 253.68% |
| 2014 Q2 | 439 Million SEK | 150.86% |
| 2014 Q3 | 367 Million SEK | -16.4% |
| 2013 Q3 | 474 Million SEK | -5.58% |
| 2013 Q2 | 502 Million SEK | 221.79% |
| 2013 FY | - SEK | 8.76% |
| 2013 Q1 | 156 Million SEK | -77.81% |
| 2013 Q4 | 1.19 Billion SEK | 152.32% |
| 2012 Q4 | 703 Million SEK | 10.53% |
| 2012 Q1 | 103 Million SEK | -86.57% |
| 2012 FY | - SEK | 24.28% |
| 2012 Q2 | 271 Million SEK | 163.11% |
| 2012 Q3 | 636 Million SEK | 134.69% |
| 2011 Q2 | 303 Million SEK | 89.38% |
| 2011 Q4 | 767 Million SEK | 162.67% |
| 2011 Q3 | 292 Million SEK | -3.63% |
| 2011 Q1 | 160 Million SEK | -76.4% |
| 2011 FY | - SEK | 19.85% |
| 2010 Q1 | 97 Million SEK | 0.0% |
| 2010 Q3 | 227 Million SEK | -5.42% |
| 2010 Q4 | 678 Million SEK | 198.68% |
| 2010 Q2 | 240 Million SEK | 147.42% |
| 2010 FY | - SEK | 35.08% |
| 2009 FY | - SEK | 24.32% |
| 2008 FY | - SEK | 46.24% |
| 2007 FY | - SEK | -11.13% |
| 2006 FY | - SEK | 42.19% |
| 2005 FY | - SEK | 29.16% |
| 2004 FY | - SEK | -1.61% |
| 2003 FY | - SEK | 47.43% |
| 2002 FY | - SEK | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| American Medical Technologies Inc. | -963.95 Thousand USD | 340987.636% |
| Ansell Limited | 209.86 Million USD | -1465.796% |
| Ansell Limited | 206.3 Million USD | -1492.826% |
| BG Medicine, Inc. | - USD | -Infinity% |
| Biotage AB (publ) | 42.83 Million USD | -7570.437% |
| BioLife Sciences Inc. | - USD | -Infinity% |
| CB Scientific, Inc. | -1.62 Million USD | 202321.482% |
| Psykey, Inc. | -1.29 Million USD | 253785.621% |
| ConvaTec Group Plc | 455.5 Million USD | -621.405% |
| ConvaTec Group Plc | 455.5 Million USD | -621.405% |
| Encision Inc. | -544.19 Thousand USD | 603927.672% |
| Golden Valley Development, Inc | -141.81 Thousand USD | 2317284.966% |
| Hear AtLast Holdings, Inc. | -109.93 Thousand USD | 2989274.93% |
| Innovative MedTech Inc. | -7.67 Million USD | 42920.933% |
| LifePoint, Inc. | -14.2 Million USD | 23237.363% |
| Medite Cancer Diagnostics, Inc. | -6.18 Million USD | 53211.363% |
| Paradigm Medical Industries, Inc. | -325 Thousand USD | 1011176.923% |
| QuantRx Biomedical Corporation | - USD | -Infinity% |
| Remedent, Inc. | -215.23 Thousand USD | 1526810.464% |
| Reflect Scientific, Inc. | -405.78 Thousand USD | 809890.43% |
| SmileDirectClub, Inc. | -186.13 Million USD | 1865.347% |
| Sector 10, Inc. | - USD | -Infinity% |
| Shandong Weigao Group Medical Polymer Company Limited | 447.82 Million USD | -633.77% |
| SheerVision, Inc. | -110.53 Thousand USD | 2973021.624% |
| United Health Products, Inc. | -2.5 Million USD | 131423.7% |
| Vasamed, Inc. | -4.57 Million USD | 71933.898% |
| Wearable Health Solutions, Inc. | -2.26 Million USD | 145450.895% |
| Yubo International Biotech Limited | -1.17 Million USD | 279121.743% |